Healthcare >> CEO Interviews >> October 12, 2001

Ted Love – Hyseq Inc (hysq)

DR. TED W. LOVE was appointed President and Chief Executive Officer of Nuvelo, Inc., in March 2001, having been appointed President and Chief Operating Officer of the company in January 2001. He has served as a Director of the company since February 2001. Dr. Love joined Nuvelo from Advanced Medicine Inc., where he served as Senior Vice President of Development from February 1998 to January 2001. Previously, Dr. Love spent six years at Genentech Inc., holding a number of senior management positions in medical affairs and product development. As Vice President of Product Development and Regulatory Affairs at Genentech, Dr. Love oversaw all drugs in development including Herceptin, Rituxan and TNKase. He also served as Chairman of Genentech's Product Development Committee. Dr. Love earned a BA in Molecular Biology from Haverford College and an MD at Yale Medical School. He completed residency and fellowship training in internal medicine and cardiology at Massachusetts General Hospital and Harvard Medical School. Following residency training, Dr. Love joined the faculty of Massachusetts General in the Department of Cardiology. He also serves as a Trustee on the Board of Managers of Haverford College and as a member of the Board of Directors of Predix Pharmaceuticals, Inc. Profile
TWST: Could we start out with an update on Hyseq, Inc., what's gone on

over the past year or so that investors should focus on?

Dr. Love: I think the main thing that we've done is made a very